Enhanced Probiotic-Based Antiviral Systems

The invention relates to improved antiviral methods and compositions incorporating probiotic bacterial molecules, enhancing efficacy, safety, and bioavailability through strategic combinations, modifications, and personalized approaches.

The original patent disclosed the use of probiotic bacterial molecules for antiviral treatment, but limitations included potential toxicity, variable efficacy, and limited bioavailability. The new inventive concept addresses these limitations by introducing novel combinations, modifications, and personalized approaches to enhance the antiviral activity of probiotic bacterial molecules.

The inventive concept comprises four primary aspects: (1) a system combining probiotic bacterial molecules with virus-targeting peptides to enhance efficacy; (2) a method for conjugating probiotic bacterial molecules to virus-binding ligands to increase their affinity for the virus; (3) a composition featuring probiotic bacterial molecules and virus-inhibiting small molecules to enhance bioavailability; and (4) a method for modifying probiotic bacterial molecules to reduce toxicity. Additionally, a system for personalized antiviral treatment is disclosed, comprising a library of probiotic bacterial molecules tailored to specific virus strains.

The new claims introduce novel combinations, modifications, and personalized approaches that significantly improve the antiviral activity, safety, and bioavailability of probiotic bacterial molecules, distinguishing them from the original patent's disclosure.

Alternative embodiments may include varying the type and ratio of probiotic bacterial molecules, using different virus-targeting peptides or ligands, and incorporating additional antiviral agents. Variations may also include adapting the inventive concept for different virus strains, administration routes, or patient populations.

The enhanced probiotic-based antiviral systems have significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of infectious disease treatment and prevention. Target markets may include hospitals, clinics, and research institutions, as well as consumers seeking alternative antiviral therapies.